



Patent- og
Varemærkestyrelsen

(12) **Oversættelse af
europæisk patentskrift**

-
- (51) Int.Cl.®: **A 61 K 9/20 (2006.01)** **A 61 K 9/48 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2009-01-12**
- (80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2008-10-15**
- (86) Europæisk ansøgning nr.: **03735628.4**
- (86) Europæisk indleveringsdag: **2003-06-16**
- (87) Den europæiske ansøgnings publiceringsdag: **2005-03-23**
- (86) International ansøgning nr.: **EP2003006314**
- (87) Internationalt publikationsnr.: **WO2003105808**
- (30) Prioritet: **2002-06-17 DE 10227077** **2002-10-25 DE 10250083**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI
SK TR**
- (73) Patenthaver: **Grünenthal GmbH, Zieglerstrasse 6, 52078 Aachen, Tyskland**
- (72) Opfinder: **BARTHOLOMÄUS, Johannes, In den Atzenbenden 54, 52080 Aachen, Tyskland**
KUGELMANN, Heinrich, Blücherplatz 7, 52068 Aachen, Tyskland
-
- (74) Fuldmægtig i Danmark: **Internationalt Patent-Bureau A/S, Rigersgade 11, 1316 København K, Danmark**
- (54) Benævnelse: **Misbrugssikret indgivelsesform**
- (56) Fremdragne publikationer:
WO-A-95/20947
WO-A-03/013476
US-A- 3 980 766
US-A- 4 070 494

The present invention relates to a solid dosage form with reduced parenteral abuse containing, in addition to one or more active ingredients with potential for abuse, at least one viscosity-increasing agent in quantities such that, on extraction with the assistance of a necessary minimum quantity of aqueous liquid, a gel is formed which
5 can still preferably pass through a needle, which gel, however, remains visually distinguishable even after being introduced into a further quantity of an aqueous liquid.

Many pharmaceutical active ingredients, in addition to having excellent activity in
10 their appropriate application, also have potential for abuse, i.e. they can be used by an abuser to bring about effects other than those intended. Opiates, for example, which are highly active in combating severe to very severe pain, are frequently used by abusers to induce a state of narcosis or euphoria.

15 Dosage forms which contain active ingredients with potential for abuse, even when taken orally in an abusively large quantity, do not usually give rise to the result desired by the abuser, namely a rapid rush or "kick", because blood levels of the active ingredients increase only slowly. In order nevertheless to achieve the desired effects and enable abuse, the corresponding dosage forms are comminuted, for
20 example ground, by the abuser and the active ingredient is extracted from the powder obtained by comminution of the dosage form with the assistance of a preferably aqueous liquid, preferably the minimum quantity necessary, and the resultant solution, optionally after filtration through cotton wool or cellulose wadding, is administered parenterally, in particular intravenously. Due to this parenteral
25 administration, only the smallest possible quantities of an aqueous liquid are used for extraction, in particular so as to obtain the smallest possible injection volume with active ingredient which results in the desired rapid rush or "kick". In this manner, parenteral administration, in comparison with oral administration, tends to give rise to an accelerated rise in levels of the active ingredient providing the abuser with the
30 desired result.

In order to prevent this form of abuse, it has been proposed in US 4,070,494 to prevent the extraction of an active ingredient from a dosage form by the addition of a

swellable agent. On addition of water, this agent swells and ensures that only a small quantity of active ingredient containing liquid is obtained which can be administered parenterally by the abuser. The majority of this dosage form which has swollen is cannot be administered.

5

A corresponding approach to the prevention of parenteral abuse also underlies the multilayer tablet disclosed in WO 95/20947 which contains the active ingredient with potential for abuse and one or more gel formers each in different layers.

- 10 According to this prior art teaching, the viscosity-increasing agents are added in quantities such that the corresponding gel cannot be administered with the assistance of conventional hypodermic needles.

- The object of the present invention was to provide a dosage form with at least
15 reduced potential for abuse for active ingredients having with such potential, which dosage form prevents any preferably still possible parenteral, in particular intravenous, abuse of the active ingredients.

- This object has been achieved by the provision of the solid dosage form according
20 to claim 1.

- For the purposes of the present invention, visually distinguishable means that the active ingredient-containing gel formed by extraction from the dosage form with the assistance of a necessary minimum quantity of aqueous liquid, when introduced with
25 a hypodermic needle with a diameter of 0.9 mm into a further quantity of aqueous liquid at 37°C, remains substantially insoluble and cohesive and cannot straightforwardly be dispersed in such a manner that it can safely be administered parenterally, in particular intravenously. The material preferably remains visually distinguishable for at least one minute, preferably for at least 10 min.

30

The increase in viscosity of the gel with the assistance of the selected viscosity-increasing agent means that, although this has been rendered more difficult, the gel may still be passed through a needle or injected. It also means that when the

resultant extract or gel is introduced at 37°C into a further quantity of aqueous liquid, for example also by injection into blood, a largely cohesive thread is initially obtained which, while it may be broken up into smaller fragments by mechanical action, it cannot be dispersed or even dissolved in such a manner that it may safely be

5 administered parenterally, in particular intravenously.

Intravenous administration of such an extract would most probably result in obstruction of blood vessels, associated with serious embolism or even death of the abuser.

10 For the purposes of the present invention, an extract or gel obtained from the dosage form according to the invention with the assistance of a necessary minimum quantity of an aqueous liquid, preferably water, is deemed to be passable through a needle if the gel formed in this manner can still be drawn up and injected back out of a hypodermic needle with a diameter of 2 mm, preferably of 1.5 mm, particularly
15 preferably of 0.6 mm. Pharmaceutical active ingredients with potential for abuse are known to the person skilled in the art, as are the quantities thereof to be used and processes for the production thereof, and may be present in the dosage form according to the invention as such, in the form of corresponding derivatives, in particular esters or ethers, or in each case in the form of corresponding
20 physiologically acceptable compounds, in particular in the form of the salts or solvates thereof. The dosage form according to the invention is also suitable for the administration of a plurality of active ingredients. It is preferably used for the administration of a single active ingredient.

25 The dosage form according to the invention is in particular suitable for preventing abuse of a pharmaceutical active ingredient selected from the group consisting of opiates, opioids, tranquillisers, preferably benzodiazepines, stimulants and other narcotics.

30 The dosage form according to the invention is very particularly preferably suitable for preventing abuse of an opiate, opioid, tranquilliser or another narcotic, which is selected from the group consisting of *N*-{1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-methoxymethyl-4-piperidyl}propionanilide (alfentanil), 5,5-diallylbarbituric acid

(allobarbitol), allylprodine, alphaprodine, 8-chloro-1-methyl-6-phenyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]-benzodiazepine (alprazolam), 2-diethylaminopropiophenone (amfepramone), (±)- α -methylphenethylamine (amphetamine), 2-(α -methylphenethylamino)-2-phenylacetonitrile (amphetaminil), 5-ethyl-5-isopentylbarbituric acid (amobarbital), anileridine, apocodeine, 5,5-diethylbarbituric acid (barbital), benzylmorphine, bezitramide, 7-bromo-5-(2-pyridyl)-1*H*-1,4-benzodiazepine-2(3*H*)-one (bromazepam), 2-bromo-4-(2-chlorophenyl)-9-methyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine (brotizolam), 17-cyclopropylmethyl-4,5 α -epoxy-7 α [(*S*)-1-hydroxy-1,2,2-trimethyl-propyl]-6-methoxy-6,14-*endo*-ethanomorphinan-3-ol (buprenorphine), 5-butyl-5-ethylbarbituric acid (butobarbital), butorphanol, (7-chloro-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2*H*-1,4-benzodiazepin-3-yl) dimethylcarbamate (camazepam), (1*S*,2*S*)-2-amino-1-phenyl-1-propanol (cathine/*D*-norpseudoephedrine), 7-chloro-*N*-methyl-5-phenyl-3*H*-1,4-benzodiazepin-2-ylamine 4-oxide (chlordiazepoxide), 7-chloro-1-methyl-5-phenyl-1*H*-1,5-benzodiazepine-2,4(3*H*,5*H*)-dione (clobazam), 5-(2-chlorophenyl)-7-nitro-1*H*-1,4-benzodiazepin-2(3*H*)-one (clonazepam), clonitazene, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-1*H*-1,4-benzodiazepine-3-carboxylic acid (clorazepate), 5-(2-chlorophenyl)-7-ethyl-1-methyl-1*H*-thieno[2,3-*e*][1,4]diazepin-2(3*H*)-one (clotiazepam), 10-chloro-11*b*-(2-chlorophenyl)-2,3,7,11*b*-tetrahydrooxazolo[3,2-*d*][1,4]benzodiazepin-6(5*H*)-one (cloxazolam), (-)-methyl-[3 β -benzoyloxy-2 β (1 α *H*,5 α *H*)-tropane carboxylate] (cocaine), 4,5 α -epoxy-3-methoxy-17-methyl-7-morphinen-6 α -ol (codeine), 5-(1-cyclohexenyl)-5-ethyl barbituric acid (cyclobarbitol), cyclorphan, cyprenorphine, 7-chloro-5-(2-chlorophenyl)-1*H*-1,4-benzodiazepin-2(3*H*)-one (delorazepam), desomorphine, dextromoramide, (+)-(1-benzyl-3-dimethylamino-2-methyl-1-phenylpropyl)propionate (dextropropoxyphene), dezocine, diampromide, diamorphine, 7-chloro-1-methyl-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-one (diazepam), 4,5 α -epoxy-3-methoxy-17-methyl-6 α -morphinan-3-ol (dihydrocodeine), 4,5 α -epoxy-17-methyl-3,6 α -morphinandiol (dihydromorphine), dimenoxadol, dimephetamol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, (6*aR*,10*aR*)-6,6,9-trimethyl-3-pentyl-6*a*,7,8,10*a*-tetrahydro-6*H*-benzo[*c*]chromen-1-ol (dronabinol), eptazocine, 8-chloro-6-phenyl-4*H*-[1,2,4]triazolo[4,3-(*a*)][1,4]benzodiazepine (estazolam), ethoheptazine, ethylmethylthiambutene, ethyl [7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-1*H*-1,4-benzodiazepine-3-carboxylate] (ethyl

loflazepate), 4,5 α -epoxy-3-ethoxy-17-methyl-7-morphinen-6 α -ol (ethylmorphine), etonitazene, 4,5 α -epoxy-7 α -(1-hydroxy-1-methylbutyl)-6-methoxy-17-methyl-6,14-endo-etheno-morphinan-3-ol (etorphine), *N*-ethyl-3-phenyl-8,9,10-trinorbornan-2-ylamine (fencamfamine), 7-[2-(α -methylphenethylamino)ethyl]-theophylline)

5 (fenethylamine), 3-(α -methylphenethylamino)propionitrile (fenproporex), *N*-(1-phenethyl-4-piperidyl)propionanilide (fentanyl), 7-chloro-5-(2-fluorophenyl)-1-methyl-1*H*-1,4-benzodiazepin-2(3*H*)-one (fludiazepam), 5-(2-fluorophenyl)-1-methyl-7-nitro-1*H*-1,4-benzodiazepin-2(3*H*)-one (flunitrazepam), 7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-1*H*-1,4-benzodiazepin-2(3*H*)-one (flurazepam), 7-chloro-5-phenyl-1-

10 (2,2,2-trifluoroethyl)-1*H*-1,4-benzodiazepin-2(3*H*)-one (halazepam), 10-bromo-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro[1,3]oxazolyl[3,2-d][1,4]benzodiazepin-6(5*H*)-one (haloxazolam), heroin, 4,5 α -epoxy-3-methoxy-17-methyl-6-morphinanone (hydrocodone), 4,5 α -epoxy-3-hydroxy-17-methyl-6-morphinanone (hydromorphone), hydroxypethidine, isomethadone, hydroxymethylmorphinan, 11-chloro-8,12b-

15 dihydro-2,8-dimethyl-12b-phenyl-4*H*-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7(6*H*)-dione (ketazolam), 1-[4-(3-hydroxyphenyl)-1-methyl-4-piperidyl]-1-propanone (ketobemidone), (3*S*,6*S*)-6-dimethylamino-4,4-diphenylheptan-3-yl acetate (levacetylmethadol (LAAM)), (-)-6-dimethylamino-4,4-diphenol-3-heptanone (levomethadone), (-)-17-methyl-3-morphinanol (levorphanol), levophenacyl-

20 morphane, lofentanil, 6-(2-chlorophenyl)-2-(4-methyl-1-piperazinylmethylene)-8-nitro-2*H*-imidazo[1,2-a][1,4]benzodiazepin-1(4*H*)-one (loprazolam), 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1*H*-1,4-benzodiazepin-2(3*H*)-one (lorazepam), 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-1*H*-1,4-benzodiazepin-2(3*H*)-one (lormetazepam), 5-(4-chlorophenyl)-2,5-dihydro-3*H*-imidazo[2,1-a]isoindol-5-ol

25 (mazindol), 7-chloro-2,3-dihydro-1-methyl-5-phenyl-1*H*-1,4-benzodiazepine (medazepam), *N*-(3-chloropropyl)- α -methylphenethylamine (mefenorex), meperidine, 2-methyl-2-propyltrimethylene dicarbamate (meprobamate), meptazinol, metazocine, methylmorphine, *N*, α -dimethylphenethylamine (metamphetamine), (\pm)-6-dimethylamino-4,4-diphenol-3-heptanone (methadone), 2-methyl-3-*o*-tolyl-4(3*H*)-

30 quinazolinone (methaqualone), methyl [2-phenyl-2-(2-piperidyl)acetate] (methylphenidate), 5-ethyl-1-methyl-5-phenylbarbituric acid (methylphenobarbital), 3,3-diethyl-5-methyl-2,4-piperidinedione (methypylon), metopon, 8-chloro-6-(2-fluorophenyl)-1-methyl-4*H*-imidazo[1,5-a][1,4]benzodiazepine (midazolam),

- 2-(benzhydrylsulfinyl)acetamide (modafinil), 4,5 α -epoxy-17-methyl-7-morphinen-3,6 α -diol (morphine), myrophine, (\pm)-*trans*-3-(1,1-dimethylheptyl)-7,8,10,10 α -tetrahydro-1-hydroxy-6,6-dimethyl-6*H*-dibenzo-[b,d]pyran-9(6*H*)-one (nabilone), nalbuphene, nalorphine, narceine, nicomorphine, 1-methyl-7-nitro-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-one (nimetazepam), 7-nitro-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-one (nitrazepam), 7-chloro-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-one (nordazepam), norlevorphanol, 6-dimethylamino-4,4-diphenyl-3-hexanone (normethadone), normorphine, norpipanone, the exudation from plants belonging to the species *Papaver somniferum* (opium), 7-chloro-3-hydroxy-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-one (oxazepam), (*cis-trans*)-10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyloxazol[3,2-d][1,4]benzodiazepin-6-(5*H*)-one (oxazolam), 4,5 α -epoxy-14-hydroxy-3-methoxy-17-methyl-6-morphinanone (oxycodone), oxymorphone, plants and parts of plants belonging to the species *Papaver somniferum* (including the subspecies *setigerum*) (*Papaver somniferum*), papaveretum, 2-imino-5-phenyl-4-oxazolidinone (pernoline), 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol (pentazocine), 5-ethyl-5-(1-methylbutyl)-barbituric acid (pentobarbital), ethyl-(1-methyl-4-phenyl-4-piperidinecarboxylate) (pethidine), phenadoxone, phenomorphane, phenazocine, phenoperidine, piminodine, pholcodeine, 3-methyl-2-phenylmorpholine (phenmetrazine), 5-ethyl-5-phenylbarbituric acid (phenobarbital), α,α -dimethyl-phenethylamine (phentermine), 7-chloro-5-phenyl-1-(2-propynyl)-1*H*-1,4-benzodiazepin-2(3*H*)-one (pinazepam), α -(2-piperidyl)benzhydryl alcohol (pipradrol), 1'-(3-cyano-3,3-diphenylpropyl)[1,4'-bipiperidine]-4'-carboxamide (piritramide), 7-chloro-1-(cyclopropylmethyl)-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-one (prazepam), profadol, proheptazine, promedol, properidine, propoxyphene, *N*-(1-methyl-2-piperidinoethyl)-*N*-(2-pyridyl)propionamide, methyl {3-[4-methoxycarbonyl-4-(*N*-phenylpropanamido)piperidino]propanoate} (remifentanil), 5-sec-butyl-5-ethylbarbituric acid (secbutabarbital), 5-allyl-5-(1-methylbutyl)-barbituric acid (secobarbital), *N*-(4-methoxymethyl-1-[2-(2-thienyl)ethyl]-4-piperidyl)propionanilide (sufentanil), 7-chloro-2-hydroxy-methyl-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-one (temazepam), 7-chloro-5-(1-cyclohexenyl)-1-methyl-1*H*-1,4-benzodiazepin-2(3*H*)-one (tetrazepam), ethyl (2-dimethylamino-1-phenyl-3-cyclohexene-1-carboxylate) (tilidine, *cis* and *trans*), tramadol, 8-chloro-6-(2-chlorophenyl)-1-methyl-4*H*-

[1,2,4]triazolo[4,3-a][1,4]benzodiazepine (triazolam), 5-(1-methylbutyl)-5-vinylbarbituric acid (vinylbital), (1*R**,2*R**)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, (1*R*,2*R*,4*S*)-2-(dimethylamino)methyl-4-(p-fluorobenzyloxy)-1-(m-methoxyphenyl) cyclohexanol and for corresponding stereoisomeric compounds, the
5 corresponding derivatives thereof in each case, in particular esters or ethers, and the physiologically acceptable compounds thereof in each case, in particular the salts and solvates thereof.

The compounds (1*R**,2*R**)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and
10 (1*R*,2*R*,4*S*)-2-(dimethylamino)methyl-4-(p-fluorobenzyloxy)-1-(m-methoxyphenyl)-cyclohexanol, the physiologically acceptable compounds thereof, in particular the hydrochlorides thereof and processes for the production thereof are respectively known, for example, from EP-A-693475 and EP-A-780369. The corresponding
descriptions are hereby introduced as a reference and are deemed to be part of the
15 disclosure.

In order to verify whether a viscosity-increasing agent is suitable for use in the dosage form according to the invention, said agent is first formulated in a corresponding dosage form in quantities such that there is no appreciable ($\pm 5\%$)
20 influence on active ingredient release relative to a dosage form without viscosity-increasing agent. The corresponding dosage form is moreover comminuted, preferably ground, and extracted with 10 ml water at 25°C. If a gel is furthermore formed which meets the above-stated conditions, the corresponding viscosity-increasing agent is suitable for the production of a dosage form according to the
25 invention.

Preferably, one or more viscosity-increasing agents are used in the dosage form according to the invention, said agents being selected from the group consisting of microcrystalline cellulose with 11 wt.% carboxymethylcellulose sodium (Avicel® RC
30 591), carboxymethylcellulose sodium (Blanose®, CMC-Na C3001P®, Frimulsion BLC-5®, Tylose C300 P®), polyacrylic acid (Carbopol® 980 NF, Carbopol® 981), locust bean flour (Cesagum® LA-200, Cesagum® LID/150, Cesagum® LN-1), pectins, preferably from citrus fruits or apples (Cesapectin® HM Medium Rapid Set), waxy

maize starch (C*Gel 04201[®]), sodium alginate (Frimulsion ALG (E401)[®]), guar flour (Frimulsion BM[®], Polygum 2611-75[®]), iota-carrageenan (Frimulsion D021[®]), karaya gum, gellan gum (Kelcogel F[®], Kelcogel LT100[®]), galactomannan (Meyprogat 150[®]), tara stone flour (Polygum 4311[®]), propylene glycol alginate (Protanal-Ester SD-LB[®]),
5 sodium hyaluronate, tragacanth, tara gum (Vidogum SP 200[®]), fermented polysaccharide welan gum (K1A96), xanthans such as xanthan gum (Xantural 180[®]). The names stated in brackets are the trade names by which the materials are known commercially.

- 10 In general, a quantity of 0.1 to 25 wt.%, preferably of 0.5 to 15 wt.%, particularly preferably of 1-10 wt.% of the viscosity-increasing agent, relative to the total formulation, is sufficient in order to meet the above-stated conditions.
The viscosity-increasing agents are preferably present in the dosage form according to the invention in quantities of ≥ 5 mg, particularly preferably of ≥ 10 mg per dosage
15 form, i.e. per administration unit.

In a particularly preferred embodiment of the present invention, the viscosity-increasing agents used are those which, in addition to the above-stated conditions, also form a gel which encloses air bubbles on extraction from the dosage form with
20 the necessary minimum quantity of aqueous liquid. The resultant gels are distinguished by a turbid appearance, which provides the potential abuser with an additional optical warning and discourages him/her from administering the gel parenterally.

- 25 The active ingredient or ingredients with potential for abuse and the viscosity-increasing agents and optionally physiologically acceptable auxiliary substances may be formulated to yield the dosage form according to the invention in accordance with conventional methods known to the person skilled in the art. Corresponding methods for formulating the dosage form according to the invention are known per
30 se to the person skilled in the art, for example from "Coated Pharmaceutical Dosage Forms - Fundamentals, Manufacturing Techniques, Biopharmaceutical Aspects, Test Methods and Raw Materials" by Kurt H. Bauer, K. Lehmann, Hermann P. Osterwald, Rothgang, Gerhart, 1st edition, 1998, Medpharm Scientific Publishers.

The corresponding literature description is hereby introduced as a reference and is deemed to be part of the disclosure.

Surprisingly, due to the inventive selection of the viscosity-increasing agents, it is possible to combine the active ingredients and the viscosity-increasing agents in the dosage form according to the invention without spatial separation from one another, without there being any impairment of release of the active ingredient from the correctly administered dosage form relative to a corresponding dosage form which does not comprise the viscosity-increasing agent.

Obviously, however, it is also possible to combine the viscosity-increasing agents and the active ingredients in the dosage form in a mutually spatially separated arrangement.

The parenteral abuse-proofed solid dosage forms according to the invention are preferably suitable for oral or rectal administration, particularly preferably for oral administration.

Where the dosage form according to the invention is intended for rectal administration, it preferably assumes the form of a suppository.

If the dosage form according to the invention is intended for oral administration, it preferably assumes the form of a tablet, a capsule or of an oral osmotic therapeutic system (OROS).

Oral osmotic therapeutic systems and suitable materials and processes for the production thereof are known per se to the person skilled in the art, for example from US 4,612,008, US 4,765,989 and US 4,783,337. The corresponding descriptions are hereby introduced as a reference and are deemed to be part of the disclosure.

The corresponding oral osmotic therapeutic system may preferably assume the form of a single or twin chamber system, in each case with a single layer or multilayer structure. In these systems, the push layer, i.e. the layer which produces the osmotic pressure by swelling, by means of which the overlying layer is expelled from the

system, preferably at least in part consists of the viscosity-increasing agents used according to the invention.

5 In a further preferred embodiment of the present invention, the orally administrable dosage form according to the invention assumes multiparticulate form containing in each case the complete mixture of active ingredient and viscosity-increasing agent, preferably in the form of microtablets, microcapsules, micropellets, granules, spheroids, beads or pellets, preferably packaged in capsules or press-moulded into tablets. The multiparticulate forms preferably have a size in the range from 0.1 to
10 3 mm, particularly preferably in the range from 0.5 to 2 mm.

The dosage form according to the invention may preferably also comprise one or more active ingredients, blended with the viscosity-increasing agent, at least in part in delayed-release form, wherein delayed release may be achieved with the
15 assistance of conventional materials and processes known to the person skilled in the art, for example by embedding the active ingredient in a delayed-release matrix or by applying one or more delayed-release coatings.

Delayed release of the active ingredient may preferably also be achieved by
20 purposeful selection of one or more of the above-stated viscosity-increasing agents in suitable quantities as the matrix material. The person skilled in the art may determine the agents and the quantity thereof suitable for the particular desired release by simple preliminary testing, wherein it must, of course, be ensured that, as described above, gel formation occurs when the attempt is made to abuse the
25 resultant dosage form.

In any event, it must be ensured that the delayed-release auxiliary substances, and likewise further optionally present auxiliary substances, do not interfere with gel formation or impair the stability of the gel which is formed.

30 If the dosage form according to the invention is intended for oral administration, it may also comprise a coating which is resistant to gastric juices and dissolves as a function of the pH value of the release environment.

By means of this coating, it is possible to ensure that, when correctly administered, the dosage form according to the invention passes through the stomach undissolved and the active ingredient is only released in the intestines. The coating which is resistant to gastric juices preferably dissolves at a pH value of between 5 and 7.5.

5

Corresponding materials and methods for the controlled release of active ingredients and for the application of coatings which are resistant to gastric juices are known to the person skilled in the art, for example from "Coated Pharmaceutical Dosage Forms - Fundamentals, Manufacturing Techniques, Biopharmaceutical Aspects, Test Methods and Raw Materials" by Kurt H. Bauer, K. Lehmann, Hermann P. Osterwald, Rothgang, Gerhart, 1st edition, 1998, Medpharm Scientific Publishers. The corresponding literature description is hereby introduced as a reference and is deemed to be part of the disclosure.

10

In a further preferred embodiment, the dosage form according to the invention contains the active ingredient not only in its delayed-release form, but also in its non-delayed-release form. By combination with the immediately released active ingredient, it is possible to obtain an initial dose for rapid pain relief. The slow release from the delayed-release form then prevents any rapid decline in action.

15

The invention is explained below with reference to Examples. These explanations are given merely by way of example and do not restrict the general concept of the invention.

20

Examples:**Example 1**

- 5 Matrix tablets with the following composition per tablet

(-)-(1 <i>R</i> ,2 <i>R</i>)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol hydrochloride	100 mg
Hydroxypropylmethylcellulose (Metolose 90 SH 100,000 from Shinetsu), 100,000 mPa·s	70 mg
Xanthan, NF	10 mg
Microcrystalline cellulose (Avicel PH 102 from FMC)	123 mg
Highly disperse silicon dioxide	4 mg
Magnesium stearate	3 mg
Total quantity	310 mg

- were produced in the following manner in a batch size of 1000 tablets: All the constituents were weighed out and screened in a Quadro Comil U10 screening machine using a screen size of 0.813 mm, mixed in a container mixer (Bohle LM 40) for 15 min \pm 15 s at a rotational speed of 20 \pm 1 rpm and pressed on a Korsch EKO eccentric press to form biconvex tablets with a diameter of 10 mm, a radius of curvature of 8 mm and an average tablet weight of 310 mg.
- 15 In vitro release was determined using the Ph. Eur. paddle method at 75 rpm in 900 ml of pH 6.8 buffer to Ph. Eur. at 37°C, with detection by UV spectrometry, and is shown in the following Table, together with a comparison with a corresponding tablet with 80 mg of hydroxypropylmethylcellulose ("HPMC") without addition of xanthan.

Time [min]	Total quantity of active ingredient released [%] from tablets according to Example 1 (70 mg HPMC +10 mg xanthan)	Total quantity of active ingredient released [%] from tablets with 80 mg HPMC (without xanthan)
0	0	0
30	19	18
240	62	59
480	83	80
600	88	87
720	93	93

One of the tablets containing xanthan was ground and shaken with 10 ml of water. A viscous, turbid suspension formed. Once the coarse, solid components of the suspension had settled out, the gel which had formed was drawn up into a syringe with a 0.9 mm diameter needle. The drawn up gel was injected into water at 37°C and threads, which did not mix with the water, with the diameter of the needle remained clearly discernible. While the threads could be broken up by stirring, they could not be dissolved and the thread fragments remained visible to the naked eye. Were such an extract to be injected into blood vessels, vessel blockages would occur.

Example 2 (Comparative Example regarding very poor needle passage properties).

Matrix tablets with the following composition per tablet

5

(-)-(1 <i>R</i> ,2 <i>R</i>)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol hydrochloride	100 mg	12%
Hydroxypropylmethylcellulose (Metolose 90 SH 100,000 from Shinetsu), 100,000 mPa·s	40 mg	
Xanthan, NF	40 mg	
Microcrystalline cellulose (Avicel PH 102 from FMC)	123 mg	
Highly disperse silicon dioxide	4 mg	
Magnesium stearate	3 mg	
Total quantity	310 mg	

were produced as stated in Example 1 and their release characteristics were investigated.

Time [min]	Total quantity of active ingredient released [%]
0	0
30	19
240	61
480	81
600	87
720	91

10

One of the tablets was ground and shaken with 10 ml of water. A viscous, turbid suspension with enclosed air bubbles formed, the viscosity of which was greater than in Example 1. Once the coarse, solid components of the suspension had settled out, the gel which had formed was drawn up into a syringe with a 0.9 mm diameter needle. The drawn up gel was injected into water at 37°C and threads,

15

which did not mix with the water, with the diameter of the needle were clearly discernible. While the threads could be broken up by stirring, they could not be dissolved and the thread fragments remained visible to the naked eye. Were such a gel to be injected into blood vessels, vessel blockages would occur.

5

Example 3

Matrix tablets with the following composition per tablet

(-)-(1 <i>R</i> ,2 <i>R</i>)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol hydrochloride	100 mg
Xanthan, NF	80 mg
Microcrystalline cellulose (Avicel PH 102 from FMC)	123 mg
Highly disperse silicon dioxide	4 mg
Magnesium stearate	3 mg
Total quantity	310 mg

10

were produced as stated in Example 1.

One of these tablets was ground and shaken with 10 ml of water. A viscous, turbid suspension, which had enclosed air bubbles, formed, the viscosity of which was higher than in Example 1. Once the coarse, solid components of the suspension had settled out, the gel which had formed was drawn up into a syringe with a 0.9 mm diameter needle. The drawn up gel was injected into water at 37°C and clearly discernible threads, which did not mix with the water, with the diameter of the needle were visible. While the threads could be broken up by stirring, they could not be dissolved and the thread fragments remained visible to the naked eye. Were such a gel to be injected into blood vessels, vessel blockages would occur.

15

20

Examples 4-7

Matrix tablets with the following composition per tablet

Example	4	5	6	7
(-)-(1 <i>R</i> ,2 <i>R</i>)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol hydrochloride	100 mg	100 mg	100 mg	100 mg
Hydroxypropylmethylcellulose (Metolose 90 SH 100,000 from Shinetsu), 100,000 mPa·s	80 mg	80 mg	80 mg	80 mg
Carboxymethylcellulose (Tylose C300)	10 mg			
Carboxymethylcellulose (Tylose C600)		10 mg		
Hydroxyethylcellulose (Tylose H300)			10 mg	
Hydroxyethylcellulose (Tylose H4000)				10 mg
Microcrystalline cellulose (Avicel PH 102 from FMC)	123 mg	123 mg	123 mg	123 mg
Highly disperse silicon dioxide	4 mg	4 mg	4 mg	4 mg
Magnesium stearate	3 mg	3 mg	3 mg	3 mg
Total quantity	320 mg	320 mg	320 mg	320 mg

5

were produced as stated in Example 1.

One of each of these tablets was ground and shaken with 10 ml of water. A viscous, turbid suspension with enclosed air bubbles formed. Once the coarse, solid

10 components of the suspension had settled out, the gel was drawn up into a syringe with a 0.9 mm diameter needle. The drawn up gel was injected into water at 37°C and clearly visible threads, which did not mix with the water, with the diameter of the needle, remained discernible. While the threads could be broken up by stirring, they could not be dissolved and the thread fragments remained visible to the naked eye.

15 Were such a gel to be injected into blood vessels, vessel blockages would occur.

Examples 8-13

Matrix tablets with the following composition per tablet

Example	8	9	10	11	12	13
Morphine sulfate pentahydrate	60 mg	60 mg	60 mg	60 mg	60 mg	60 mg
Hydroxypropylmethylcellulose (Metolose 90 SH 15,000 from Shinetsu), 15,000 mPa·s	60 mg	60 mg	60 mg	60 mg	60 mg	60 mg
Xanthan, NF	10 mg	30 mg				
Carboxymethylcellulose (Tylose C300)			10 mg			
Carboxymethylcellulose (Tylose C600)				10 mg		
Hydroxyethylcellulose (Tylose H300)					10 mg	
Hydroxyethylcellulose (Tylose H4000)						10 mg
Microcrystalline cellulose (Avicel PH 102 from FMC)	123 mg	123 mg	123 mg	123 mg	123 mg	123 mg
Highly disperse silicon dioxide	4 mg	4 mg	4 mg	4 mg	4 mg	4 mg
Magnesium stearate	3 mg	3 mg	3 mg	3 mg	3 mg	3 mg

5

One of each of these tablets was ground and shaken with 10 ml of water. A viscous, turbid suspension with enclosed air bubbles formed. Once the coarse, solid components of the suspension had settled out, the gel was drawn up into a syringe with a 0.9 mm diameter needle. The drawn up gel was injected into water at 37°C and clearly visible threads, which did not mix with the water, with the diameter of the needle, remained discernible. While the threads could be broken up by stirring, they could not be dissolved and the thread fragments remained visible to the naked eye. Were such a gel to be injected into blood vessels, vessel blockages would occur.

10

Examples 14-18

Capsules with the following composition of the simple powder mixture per capsule
(size 4 capsule)

5

Example	14	15	16	17	18
Morphine sulfate pentahydrate	20 mg	20 mg	20 mg	20 mg	20 mg
Xanthan, NF	10 mg				
Carboxymethylcellulose (Tylose C300)		10 mg			
Carboxymethylcellulose (Tylose C600)			10 mg		
Hydroxyethylcellulose (Tylose H300)				10 mg	
Hydroxyethylcellulose (Tylose H4000)					10 mg
Microcrystalline cellulose (Avicel PH 102 from FMC)	68 mg	68 mg	68 mg	68 mg	68 mg
Highly disperse silicon dioxide	1 mg	1 mg	1 mg	1 mg	1 mg
Magnesium stearate	1 mg	1 mg	1 mg	1 mg	1 mg

One of each of these tablets was ground and shaken with 10 ml of water. A viscous, turbid suspension with enclosed air bubbles formed. Once the coarse, solid components of the suspension had settled out, the gel was drawn up into a syringe with a 0.9 mm diameter needle. The drawn up gel was injected into water at 37°C and clearly visible threads, which did not mix with the water, with the diameter of the needle, remained discernible. While the threads could be broken up by stirring, they could not be dissolved and the thread fragments remained visible to the naked eye. Were such a gel to be injected into blood vessels, vessel blockages would occur.

10

15

P A T E N T K R A V

1. Fast indgivelsesform sikret mod parenteralt misbrug, k e n d e t e g n e t ved, at den du over et eller flere aktive midler med misbrugspotentiale opviser mindst et viskositetsforhøjende middel i sådanne mængder, at det i en ved hjælp af 10 ml vand ved 25°C

5 udvundet ekstrakt af indgivelsesformen danner en aktivmiddelholdig, stadig nålepasserbar gel, der ved Indføring via en injektionsnål med en diameter på 0,9 mm i en yderligere mængde vand ved 37°C kan skelnes visuelt i mindst 1 minut.

2. Indgivelsesform ifølge krav 1, k e n d e t e g n e t ved, at det aktive middel er et farmaceutisk aktivt middel valgt fra gruppen af opiater, opioider, beroligende midler og fo-

10 retrukket benzodizepiner, stimulanser og yderligere bedøvelsesmidler.

3. Indgivelsesform ifølge krav 2, k e n d e t e g n e t ved, at det aktive middel er et opiat, opioid, beroligende middel eller et yderligere bedøvelsesmiddel valgt fra gruppen be-
stående af

N-{1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-methoxymethyl-4-piperidyl}propionanilid

15 (alfentanil),

5,5-diallylbarbitursyre (allobarbital),

allylprodin,

alphaprodin,

8-chlor-1-methyl-6-phenyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]-benzodiazepin (alprazolam),

20 2-diethylaminopropiophenon (amfepramone),

(±)- α -methylphenethylamin (amfetamin),

2-(α -methylphenethylamino)-2-phenylacetonitril (amphetaminil),

5-ethyl-5-isopentylbarbitursyre (amobarbital),

anileridin,

25 apocodein,

5,5-diethylbarbitursyre (barbital),

benzylmorphin,

bezitramid,

1-brom-5-(2-pyridyl)-1*H*-1,4-benzodiazepin-2(3*H*)-on (bromazepam),

30 2-brom-4-(2-chlorphenyl)-9-methyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin
(brotizolam),

17-cyclopropylmethyl-4,5*a*-epoxy-7*a*[(*S*)-1-hydroxy-1,2,2-trimethyl-propyl]-6-methoxy-

6,14-*endo*-ethanomorphinan-3-ol (buprenorphin),

5-butyl-5-ethylbarbitursyre (butobarbital),

35 butorphanol,

(7-chlor-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2*H*-1,4-benzodiazepin-3-yl) dimethylcarbam-
mat (camazepam),

(1*S*,2*S*)-2-amino-1-phenyl-1-propanol (cathin/D-norpseudoephedrin),

7-chlor-*N*-methyl-5-phenyl-3*H*-1,4-benzodiazepin-2-ylamin 4-oxid (chlordiazepoxid),

40 7-chlor-1-methyl-5-phenyl-1*H*-1,5-benzodiazepin-2,4(3*H*,5*H*)-dion (clobazam),

5-(2-chlorphenyl)-7-nitro-1*H*-1,4-benzodiazepin-2(3*H*)-on (clonazepam),

- clonitazen,
 7-chlor-2,3-dihydro-2-oxo-5-phenyl-1*H*-1,4-benzodiazepin-3-carboxylsyre (clorazepat),
 5-(2-chlorphenyl)-7-ethyl-1-methyl-1*H*-thieno[2,3-*e*][1,4]diazepin-2(3*H*)-on (clotiazepam),
 10-chlor-11*b*-(2-chlorphenyl)-2,3,7,11*b*-tetrahydrooxazolo[3,2-*d*][1,4]benzodiazepin-
 5 6(5*H*)-on (cloxazolam),
 (-)-methyl-[3*β*-benzoyloxy-2*β*-(1*αH*,5*αH*)-tropancarboxylat] (cocain),
 4,5*α*-epoxy-3-methoxy-17-methyl-7-morphinen-6*α*-ol (codein),
 5-(1-cyclohexenyl)-5-ethylbarbitursyre (cyclobarbital),
 cyclorphan,
 10 cyprenorphin,
 7-chlor-5-(2-chlorphenyl)-1*H*-1,4-benzodiazepin-2(3*H*)-on (delorazepam),
 desomorphin,
 dextromoramid,
 (+)-(1-benzyl-3-dimethylamino-2-methyl-1-phenylpropyl)propionat (dextropropoxyphen),
 15 dezocin,
 diampromid,
 diamorphon,
 7-chlor-1-methyl-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-on (diazepam),
 4,5*α*-epoxy-3-methoxy-17-methyl-6*α*-morphinanol (dihydrocodein),
 20 4,5*α*-epoxy-17-methyl-3,6*α*-morphinandiol (dihydromorphin),
 dimenoxadol,
 dimephetamol,
 dimethylthiambuten,
 dioxaphetylbutyrat,
 25 dipipanon,
 (6*aR*,10*aR*)-6,6,9-trimethyl-3-pentyl-6*a*,7,8,10*a*-tetrahydro-6*H*-benzo[*c*]chromen-1-ol
 (dronabinol),
 eptazocin,
 8-chlor-6-phenyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepin (estazolam),
 30 ethoheptazin,
 ethylmethylthiambuten,
 ethyl-[7-chlor-5-(2-fluorphenyl)-2,3-dihydro-2-oxo-1*H*-1,4-benzodiazepin-3-carboxylat]
 (ethylloflazepat),
 4,5*α*-epoxy-3-ethoxy-17-methyl-7-morphinen-6*α*-ol (ethylmorphin),
 35 etonitazen,
 4,5*α*-epoxy-7*α*-(1-hydroxy-1-methylbutyl)-6-methoxy-17-methyl-6,14-*endo*-ethenomorph-
 inan-3-ol (etorphin),
N-ethyl-3-phenyl-8,9,10-trinorboman-2-ylamin (fencamfamin),
 7-[2-(*α*-methylphenethylamino)ethyl]theophyllin (fenethylin),
 40 3-(*α*-methylphenethylamino)propionitril (fenproporex),
N-(1-phenethyl-4-piperidyl)propionanilid (fentanyl),

- 7-chlor-5-(2-fluorphenyl)-1-methyl-1*H*-1,4-benzodiazepin-2(3*H*)-on (fludiazepam),
 5-(2-fluorphenyl)-1-methyl-7-nitro-1*H*-1,4-benzodiazepin-2(3*H*)-on (flunitrazepam),
 7-chlor-1-(2-diethylaminoethyl)-5-(2-fluorphenyl)-1*H*-1,4-benzodiazepin-2(3*H*)-on (flurazepam),
- 5 7-chlor-5-phenyl-1-(2,2,2-trifluorethyl)-1*H*-1,4-benzodiazepin-2(3*H*)-on (halazepam),
 10-brom-11b-(2-fluorphenyl)-2,3,7,11b-tetrahydro[1,3]oxazolyl[3,2-*d*][1,4]benzodiazepin-6(5*H*)-on (haloxazolam),
 heroin,
 4,5*α*-epoxy-3-methoxy-17-methyl-6-morphinanon (hydrocodon),
- 10 4,5*α*-epoxy-3-hydroxy-17-methyl-6-morphinanon (hydromorphon),
 hydroxypethidin,
 isomethadon,
 hydroxymethylmorphinan,
 11-chlor-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4*H*-[1,3]oxazino[3,2-*d*][1,4]benzodiazep-
- 15 in-4,7(6*H*)-dion (ketazolam),
 1-[4-(3-hydroxyphenyl)-1-methyl-4-piperidyl]-1-propanon (ketobemidon),
 (3*S*,6*S*)-6-dimethylamino-4,4-diphenylheptan-3-ylacetat (levacetylmethadol (LAAM)),
 (-)-6-dimethylamino-4,4-diphenol-3-heptanon (levomethadon),
 (-)-17-methyl-3-morphinanol (levorphanol),
- 20 levophenacylmorphan,
 lofentanil,
 6-(2-chlorphenyl)-2-(4-methyl-1-piperazinylmethylen)-8-nitro-2*H*-imidazo[1,2-*a*][1,4]-benzodiazepin-1(4*H*)-on (loprazolam),
 7-chlor-5-(2-chlorphenyl)-3-hydroxy-1*H*-1,4-benzodiazepin-2(3*H*)-on (lorazepam),
- 25 7-chlor-5-(2-chlorphenyl)-3-hydroxy-1-methyl-1*H*-1,4-benzodiazepin-2(3*H*)-on (lormetazepam),
 5-(4-chlorphenyl)-2,5-dihydro-3*H*-imidazo[2,1-*a*]isoindol-5-ol (mazindol),
 7-chlor-2,3-dihydro-1-methyl-5-phenyl-1*H*-1,4-benzodiazepin (medazepam),
N-(3-chlorpropyl)-*α*-methylphenethylamin (mefenorex),
- 30 meperidin,
 2-methyl-2-propyltrimethylendicarbamat (meprobamat),
 meptazinol,
 metazocin,
 methylmorphin,
- 35 *N*,*α*-dimethylphenethylamin (metamphetamin),
 (±)-6-dimethylamino-4,4-diphenol-3-heptanon (methadon),
 2-methyl-3-*o*-tolyl-4(3*H*)-quinazolinon (methaqualon),
 methyl-[2-phenyl-2-(2-piperidyl)acetat] (methylphenidat),
 5¹ethyl-1-methyl-5-phenylbarbitursyre (methylphenobarbital),
- 40 3,3-diethyl-5-methyl-2,4-piperidinedion (methypylon),
 metopon,

- 8-chlor-6-(2-fluorphenyl)-1-methyl-4*H*-imidazo[1,5-*a*][1,4]benzodiazepin (midazolam),
 2-(benzhydrylsulfinyl)acetamid (modafinil),
 4,5*α*-epoxy-17-methyl-7-morphinen-3,6*α*-diol (morphin),
 myrophin,
- 5 (±)-*trans*-3-(1,1-dimethylheptyl)-7,8,10,10*α*-tetrahydro-1-hydroxy-6,6-dimethyl-6*H*-di-
 benzo[*b,d*]pyran-9(6*αH*)-on (nabilon),
 nalbuphen,
 nalorphen,
 narcein,
- 10 nicomorphin,
 1-methyl-7-nitro-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-on (nimetazepam),
 7-nitro-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-on (nitrazepam),
 7-chlor-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-on (nordazepam),
 norlevorphanol,
- 15 6-dimethylamino-4,4-diphenyl-3-hexanon (normethadon),
 normorphin, norpipanon,
 udskilt saft fra planter tilhørende arten *Papaver somniferum* (opium),
 7-chlor-3-hydroxy-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-on (oxazepam),
 (*cis-trans*)-10-chlor-2,3,7,11*b*-tetrahydro-2-methyl-11*b*-phenyloxazolo[3,2-*d*][1,4]benzo-
- 20 diazepin-6-(5*H*)-on (oxazolam),
 4,5*α*-epoxy-14-hydroxy-3-methoxy-17-methyl-6-morphinanon (oxycodon),
 oxymorphan,
 planter og plantedele fra planter tilhørende arten *Papaver somniferum* (inkluderende unde-
 rarten *setigerum*) (*Papaver somniferum*),
- 25 papaveretum,
 2-imino-5-phenyl-4-oxazolidinon (pernolin),
 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-
 8-ol (pentazocin),
 5-ethyl-5-(1-methylbutyl)barbitursyre (pentobarbital),
- 30 ethyl-(1-methyl-4-phenyl-4-piperidincarboxylat) (pethidin),
 phenadoxon,
 phenomorphan,
 phenazocin,
 phenoperidin,
- 35 pimminodin,
 pholcodein,
 3-methyl-2-phenylmorpholin (phenmetrazin),
 5-ethyl-5-phenylbarbitursyre (phenobarbital),
 α,α -dimethylphenethylamin (phentermin),
- 40 7-chlor-5-phenyl-1-(2-propynyl)-1*H*-1,4-benzodiazepin-2(3*H*)-on (pinazepam),
 α -(2-piperidyl)benzhydrylalkohol (pipradrol),

- 1'-(3-cyano-3,3-diphenylpropyl)[1,4'-bipiperidin]-4'-carboxamid (piritramid),
 7-chlor-1-(cyclopropylmethyl)-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-on (prazepam),
 profadol,
 proheptazin,
 5 promedol,
 properidin,
 propoxyphen,
N-(1-methyl-2-piperidinoethyl)-*N*-(2-pyridyl)propionamid,
 methyl-{3-[4-methoxycarbonyl-4-(*N*-phenylpropanamido)piperidino]propanoat} (remifen-
 10 tanil),
 5-sec-butyl-5-ethylbarbitursyre (secbutabarbitol),
 5-allyl-5-(1-methylbutyl)barbitursyre (secobarbital),
N-(4-methoxymethyl-1-[2-(2-thienyl)ethyl]-4-piperidyl}propionanilid (sufentanil),
 7-chlor-2-hydroxymethyl-5-phenyl-1*H*-1,4-benzodiazepin-2(3*H*)-on (temazepam),
 15 7-chlor-5-(1-cyclohexenyl)-1-methyl-1*H*-1,4-benzodiazepin-2(3*H*)-on (tetrazepam),
 ethyl-(2-dimethylamino-1-phenyl-3-cyclohexen-1-carboxylat) (tilidin, *cis* og *trans*)),
 tramadol,
 8-chlor-6-(2-chlorphenyl)-1-methyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepin (triazol-
 am),
 20 5-(1-methylbutyl)-5-vinylbarbitursyre (vinylbital),
 (1*R**,2*R**)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol,
 (1*R*,2*R*,4*S*)-2-(dimethylamino)methyl-4-(*p*-fluorbenzyloxy)-1-(*m*-methoxyphenyl)cyclohex-
 anol,
 og de i hvert tilfælde korresponderende stereoisomere forbindelser og de hertil svarende
 25 derivater, især estere eller ethere og i hvert tilfælde disses fysiologisk acceptable forbindel-
 ser, især salte og solvater.

4. Indgivelsesform ifølge krav 2 eller 3, *k e n d e t e g n e t* ved, at den opviser et
 stimulerende middel valgt fra gruppen bestående af amfetamin, norpseudoephedrin,
 methylphenidat og i hvert tilfælde deres eventuelle fysiologisk forbindelser, især deres ba-
 30 ser, salte og solvater.

5. Indgivelsesform ifølge et af kravene 1 til 4, *k e n d e t e g n e t* ved, at den opvi-
 ser et eller flere viskositetsforhøjende midler valgt fra gruppen bestående af mikrokystal-
 linsk cellulose med 11 vægt% Na-carboxymethylcellulose, Na-carboxymethylcellulose, po-
 lyacrylsyre, johannesbrødkernemel, citruspektin, voksmajsstivelse, natriumalginat, guar-
 35 kernemel, iota-carrageenan, karayagummi, gellangummi, galaktomannan, tarakernemel,
 propylenglycoalginat, æblepektin, pektin fra citronskræller, Na-hyaluronat, tragant, tara-
 gummi, fermenteret polysaccharid-welangummi og xanthangummi.

6. Indgivelsesform ifølge et af kravene 1 til 5, *k e n d e t e g n e t* ved, at den opvi-
 ser det viskositetsforhøjende middel i en mængde på ≥ 5 mg pr. indgivelsesform, altså pr.
 40 doseringsenhed.

7. Indgivelsesform ifølge et af kravene 1 til 6 til oral anvendelse.

8. Indgivelsesform ifølge krav 7, k e n d e t e g n e t ved, at den foreligger i form af en tablet, en kapsel eller i form af et oralt osmotisk terapeutisk system (OROS).

9. Indgivelsesform ifølge krav 7, k e n d e t e g n e t ved, at den foreligger i multi-partikelform, fortrinsvis i form af mikrotabletter, mikrokapsler, mikropellets, granulater, 5 sfæroider, perler eller pellets, der foretrukket er fyldt i kapsler eller er presset til tabletter.

10. Indgivelsesform ifølge et af kravene 1 til 9, k e n d e t e g n e t ved, at den indeholder mindst et aktivt middel, der i det mindste delvis er i retarderet form.

11. Indgivelsesform ifølge et af kravene 8 til 10, k e n d e t e g n e t ved, at den opviser et mavesaftresistent overtræk.